PL3204030T3 - Terapia skojarzona zakażenia hbv i hdv - Google Patents

Terapia skojarzona zakażenia hbv i hdv

Info

Publication number
PL3204030T3
PL3204030T3 PL15775453.2T PL15775453T PL3204030T3 PL 3204030 T3 PL3204030 T3 PL 3204030T3 PL 15775453 T PL15775453 T PL 15775453T PL 3204030 T3 PL3204030 T3 PL 3204030T3
Authority
PL
Poland
Prior art keywords
hbv
combined therapy
hdv infection
hdv
infection
Prior art date
Application number
PL15775453.2T
Other languages
English (en)
Inventor
Alexander ALEXANDROV
Original Assignee
Myr Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myr Gmbh filed Critical Myr Gmbh
Publication of PL3204030T3 publication Critical patent/PL3204030T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10133Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10171Demonstrated in vivo effect
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10111Deltavirus, e.g. hepatitis delta virus
    • C12N2760/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10111Deltavirus, e.g. hepatitis delta virus
    • C12N2760/10133Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10111Deltavirus, e.g. hepatitis delta virus
    • C12N2760/10171Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Rectifiers (AREA)
  • Peptides Or Proteins (AREA)
PL15775453.2T 2014-10-07 2015-10-07 Terapia skojarzona zakażenia hbv i hdv PL3204030T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14187865 2014-10-07
PCT/EP2015/073173 WO2016055534A2 (en) 2014-10-07 2015-10-07 Combination therapy of hbv and hdv infection

Publications (1)

Publication Number Publication Date
PL3204030T3 true PL3204030T3 (pl) 2022-09-19

Family

ID=51790567

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15775453.2T PL3204030T3 (pl) 2014-10-07 2015-10-07 Terapia skojarzona zakażenia hbv i hdv

Country Status (11)

Country Link
US (2) US20180228804A1 (pl)
EP (2) EP3204030B1 (pl)
KR (2) KR20230156963A (pl)
CN (2) CN115920061A (pl)
CA (3) CA3175236C (pl)
EA (1) EA201790786A1 (pl)
ES (1) ES2922883T3 (pl)
PL (1) PL3204030T3 (pl)
PT (1) PT3204030T (pl)
SI (1) SI3204030T1 (pl)
WO (1) WO2016055534A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499722B (zh) 2012-11-12 2024-08-23 海德堡吕布莱希特-卡尔斯大学 用于治疗肝脏疾病和心血管疾病的脂肽
AU2017274094B2 (en) 2016-05-30 2020-09-10 Shanghai Hep Pharmaceutical Co., Ltd. Compositions and methods for treating metabolic diseases
EP3392267A1 (en) * 2017-04-18 2018-10-24 Myr GmbH Therapy of atherosclerosis, primary biliary cirrhosis and nrlp3 inflammasome-associated disease by htcp inhibitors
CN109718364A (zh) * 2017-10-27 2019-05-07 上海贺普药业股份有限公司 充分剂量条件下治疗乙肝病毒相关肝病的药物和方法
CN111867616A (zh) * 2018-01-11 2020-10-30 国立大学法人东京大学 Ntcp抑制剂
JP2023527422A (ja) * 2020-05-28 2023-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン SARS-CoV-2感染を予防および治療するための組成物および方法
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN116510021A (zh) * 2022-01-24 2023-08-01 上海贺普药业股份有限公司 有限化慢性乙肝的核苷(酸)类药物治疗的药物及方法
WO2025240242A1 (en) * 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) * 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60229126D1 (de) * 2001-05-25 2008-11-13 Dobeel Corp Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
WO2009092396A1 (en) * 2008-01-25 2009-07-30 Universitätsklinikum Heidelberg Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors
CN102015753A (zh) * 2008-01-25 2011-04-13 海德堡吕布莱希特-卡尔斯大学 乙肝病毒(HBV)的疏水性修饰的preS-衍生肽及其作为载体将化合物特异性递送到肝脏的用途
CN109354623B (zh) * 2012-04-25 2022-06-24 华辉安健(北京)生物科技有限公司 乙肝肝炎病毒功能性受体的组成以及相关应用
CN111499722B (zh) * 2012-11-12 2024-08-23 海德堡吕布莱希特-卡尔斯大学 用于治疗肝脏疾病和心血管疾病的脂肽

Also Published As

Publication number Publication date
ES2922883T3 (es) 2022-09-21
EP4098273A1 (en) 2022-12-07
EP3204030A2 (en) 2017-08-16
US20180228804A1 (en) 2018-08-16
CA3175236C (en) 2025-10-14
EA201790786A1 (ru) 2017-09-29
CA3175236A1 (en) 2016-04-14
CA2959465C (en) 2024-05-21
CN115920061A (zh) 2023-04-07
CA3175242A1 (en) 2016-04-14
CN107106686A (zh) 2017-08-29
EP3204030B1 (en) 2022-04-27
WO2016055534A3 (en) 2016-06-09
PT3204030T (pt) 2022-08-05
US20220040178A1 (en) 2022-02-10
WO2016055534A2 (en) 2016-04-14
KR102599942B1 (ko) 2023-11-09
KR20230156963A (ko) 2023-11-15
SI3204030T1 (sl) 2022-10-28
CN107106686B (zh) 2022-09-27
KR20170066339A (ko) 2017-06-14
CA2959465A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
NL301322I2 (nl) Repotrectinib en/of farmaceutisch aanvaardbare zouten daarvan
PL3402888T3 (pl) Środki i sposoby leczenia hbv
IL252602B (en) Oral care compositions and methods of use
IL262301A (en) Liposomal preparation and methods of treatment
LT3684377T (lt) Hepatito b infekcijos gydymo būdai
IL258147A (en) Combination therapy of an hbv capsid assembly inhibitor and an interferon
LT3179991T (lt) Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai
IL257663B (en) Oral care compositions and methods of use
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
PL3212174T3 (pl) Sposoby leczenia zakażeń wirusem filoviridae
PL3204030T3 (pl) Terapia skojarzona zakażenia hbv i hdv
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
HUE056287T2 (hu) Pancreatitis kezelése
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
IL251505A0 (en) Neuroactive compounds and methods of use thereof
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
LT3341027T (lt) Transfekcijos kompleksai ir jų panaudojimo būdai
DK3204497T3 (da) Terapeutisk hæmning af lactatdehydrogenase og midler dertil
EP3212170C0 (en) IMPLANTABLE MEDICAL DEVICES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS
DK3237621T3 (da) Varianter af human alpha-galactosidase
LT3119384T (lt) Intrahepatinių cholestazinių ligų gydymas